The partnership allows Roche to develop and apply Enable Injections’ expertise and enFuse technology to specific development programs. Through the collaboration, Roche can obtain a worldwide, exclusive license to develop and commercialize combinations of enFuse with specific molecules. Under the deal, Enable Injections has responsibility for clinical and commercial manufacturing and supply of enFuse.
Enable Injections designed enFuse, a mechanical, wearable drug delivery device, to deliver large volumes of small molecule and biologic medications subcutaneously. Patients can receive their needed treatment in a single injection under the skin, rather than the intravenous route.
The FDA cleared enFuse for the delivery of Empaveli in October 2023. The company says it’s the first-ever hands-free wearable technology that allows patients to self-administer large-volume medications subcutaneously without an IV or syringe pump. It expanded its manufacturing operations for enFuse in February.
Mike Hooven, chair and CEO, says the company designed enFuse to overcome IV infusion shortcomings. It enables fast, simple and convenient delivery for efficiency and value through self-administration.
“We are pleased that Roche recognizes the significant value our wearable technology brings to the patient treatment experience and look forward to serving patients through the potential of our differentiated device delivery platform with Roche’s differentiated molecules,” said Hooven.
